Endocannabinoid signals in the control of emotion

Current Opinion in Pharmacology

Volumn 9, Issue 1, 2009, Pages 46-52

  Lutz, Beat ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 4 AMINOBUTYRIC ACID; ANANDAMIDE; ANTIDEPRESSANT AGENT; CANNABINOID 1 RECEPTOR; CANNABIS; ENDOCANNABINOID; FATTY ACID AMIDASE; GLUTAMIC ACID; NEUROTRANSMITTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLACEBO; RIMONABANT; TARANABANT; TETRAHYDROCANNABINOL; VANILLOID RECEPTOR 1;

ADAPTATION; ANXIETY; ANXIETY DISORDER; AUTOCRINE EFFECT; BRAIN FUNCTION; CLINICAL TRIAL; COPING BEHAVIOR; DEPRESSION; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG TARGETING; DRUG WITHDRAWAL; EMOTIONAL STABILITY; EMOTIONALITY; ENVIRONMENTAL FACTOR; FEAR; FEEDING BEHAVIOR; HUMAN; LONG TERM DEPRESSION; LOW DRUG DOSE; MAJOR DEPRESSION; MEDICAL RESEARCH; MEMORY CONSOLIDATION; MENTAL DISEASE; NERVE CELL PLASTICITY; NEUROPROTECTION; OBESITY; PARACRINE SIGNALING; PHOBIA; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RECEPTOR OCCUPANCY; REVIEW; REWARD; SCHIZOPHRENIA; SIDE EFFECT; SIGNAL TRANSDUCTION; STIMULUS RESPONSE; STRESS; SURVIVAL RATE; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME; WEIGHT REDUCTION;

ANIMALS; EMOTIONS; ENDOCANNABINOIDS; HUMANS; MENTAL DISORDERS; NEURONAL PLASTICITY; RECEPTORS, CANNABINOID; SIGNAL TRANSDUCTION; SYNAPSES;

EID: 59349084762     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.12.001     Document Type: Review

References (65)

1. LeDoux J.E. Emotion circuits in the brain. Annu Rev Neurosci 23 (2000) 155-184
2. Pull C.B. Combined pharmacotherapy and cognitive-behavioural therapy for anxiety disorders. Curr Opin Psychiatry 20 (2007) 30-35
3. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4 (2003) 873-884
4. Pacher P., Batkai S., and Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58 (2006) 389-462
5. Ahn K., McKinney M.K., and Cravatt B.F. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 108 (2008) 1687-1707. Excellent overview on eCB synthesizing and degrading enzymes.
6. O'Sullivan S.E. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 152 (2007) 576-582
7. Marinelli S., Di M.V., Florenzano F., Fezza F., Viscomi M.T., van der S.M., Bernardi G., Molinari M., Maccarrone M., and Mercuri N.B. N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology 32 (2007) 298-308
8. Oh d.Y., Yoon J.M., Moon M.J., Hwang J.I., Choe H., Lee J.Y., Kim J.I., Kim S., Rhim H., O'Dell D.K., et al. Identification of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92. J Biol Chem 283 (2008) 21054-21064
9. Maccarrone M., Rossi S., Bari M., De Chiara V., Fezza F., Musella A., Gasperi V., Prosperetti C., Bernardi G., Finazzi-Agro A., et al. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci 11 (2008) 152-159. This work gives a novel view on the functional interaction of AEA and 2-AG.
10. Starowicz K., Nigam S., and Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 114 (2007) 13-33
11. Viveros M.P., Marco E.M., Llorente R., and Lopez-Gallardo M. Endocannabinoid system and synaptic plasticity: implications for emotional responses. Neural Plast 2007 (2007) 52908
12. Lafenetre P., Chaouloff F., and Marsicano G. The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear extinction. Pharmacol Res 56 (2007) 367-381. Comprehensive review on the role of eCBs in anxiety and fear extinction.
13. Patel S., and Hillard C.J. Adaptations in endocannabinoid signaling in response to repeated homotypic stress: a novel mechanism for stress habituation. Eur J Neurosci 27 (2008) 2821-2829. Exellent review discussing the involvement of the eCB system in the coping to stress; with relevant implications to mood disorders.
14. Steiner M.A., and Wotjak C.T. Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis. Prog Brain Res 170 (2008) 397-432
15. Bambico F.R., and Gobbi G. The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets. Expert Opin Ther Targets 12 (2008) 1347-1366
16. Lutz B. The endocannabinoid system and extinction learning. Mol Neurobiol 36 (2007) 92-101
17. Moreira F.A., and Lutz B. The endocannabinoid system: emotion, learning and addiction. Addict Biol 13 (2008) 196-212
18. Moreira FA, Grieb M, Lutz B: Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol & Metabol 2009, in press.
19. Marsicano G., Goodenough S., Monory K., Hermann H., Eder M., Cannich A., Azad S.C., Cascio M.G., Gutierrez S.O., van der Stelt M., et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302 (2003) 84-88. First report on the presence of functional CB1 receptor on forebrain glutamatergic neurons, showing the protective mechanism against excessive neuronal activity.
20. Lutz B. On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures. Biochem Pharmacol 68 (2004) 1691-1698
21. Monory K., Blaudzun H., Massa F., Kaiser N., Lemberger T., Schütz G., Wotjak C.T., Lutz B., and Marsicano G. Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice. PLoS Biol 5 (2007) e269
22. Moreira F.A., Kaiser N., Monory K., and Lutz B. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 54 (2008) 141-150
23. Moise A.M., Eisenstein S.A., Astarita G., Piomelli D., and Hohmann A.G. An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters. Psychopharmacology (Berl) 200 (2008) 333-346
24. Micale V., Cristino L., Tamburella A., Petrosino S., Leggio G.M., Drago F., and Di M.V. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 34 (2009) 593-606
25. Rubino T., Guidali C., Vigano D., Realini N., Valenti M., Massi P., and Parolaro D. CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Neuropharmacology 54 (2008) 151-160
26. 1 receptors and TRPV1 with opposing effects on anxiety.
27. Scherma M., Medalie J., Fratta W., Vadivel S.K., Makriyannis A., Piomelli D., Mikics E., Haller J., Yasar S., Tanda G., and Goldberg S.R. The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology 54 (2008) 129-140
28. 1 receptor function.
29. Zarrindast M.R., Sarahroodi S., Arzi A., Khodayar M.J., Taheri-Shalmani S., and Rezayof A. Cannabinoid CB1 receptors of the rat central amygdala mediate anxiety-like behavior: interaction with the opioid system. Behav Pharmacol 19 (2008) 716-723
30. Braida D., Limonta V., Malabarba L., Zani A., and Sala M. 5-HT1A receptors are involved in the anxiolytic effect of Delta9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats. Eur J Pharmacol 555 (2007) 156-163
31. Kamprath K., Marsicano G., Tang J., Monory K., Bisogno T., Di Marzo V., Lutz B., and Wotjak C.T. Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. J Neurosci 26 (2006) 6677-6686. Relevant work on the view that eCBs mediate habituation-like processes in fear extinction.
32. Kamprath K, Plendl W, Marsicano G, Deussing JM, Wurst W, Lutz B, Wotjak CT: Endocannabinoids mediate acute fear adaptation via glutamatergic neurons independently of CRH signaling. Genes Brain Behav 2008, in press, doi:10.1111/j.1601-183X.2008.00463.x.
33. Hölter S.M., Kallnik M., Wurst W., Marsicano G., Lutz B., and Wotjak C.T. Cannabinoid CB1 receptor is dispensable for memory extinction in an appetitively-motivated learning task. Eur J Pharmacol 510 (2005) 69-74
34. Harloe J.P., Thorpe A.J., and Lichtman A.H. Differential endocannabinoid regulation of extinction in appetitive and aversive Barnes maze tasks. Learn Mem 15 (2008) 806-809
35. Suzuki A., Mukawa T., Tsukagoshi A., Frankland P.W., and Kida S. Activation of LVGCCs and CB1 receptors required for destabilization of reactivated contextual fear memories. Learn Mem 15 (2008) 426-433
36. Resstel L.B., Lisboa S.F., Aguiar D.C., Correa F.M., and Guimaraes F.S. Activation of CB1 cannabinoid receptors in the dorsolateral periaqueductal gray reduces the expression of contextual fear conditioning in rats. Psychopharmacology (Berl) 198 (2008) 405-411
37. Lisboa S.F., Resstel L.B., Aguiar D.C., and Guimaraes F.S. Activation of cannabinoid CB1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test. Eur J Pharmacol 593 (2008) 73-78
38. Malcher-Lopes R., Di S., Marcheselli V.S., Weng F.J., Stuart C.T., Bazan N.G., and Tasker J.G. Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. J Neurosci 26 (2006) 6643-6650
39. Steiner M.A., Marsicano G., Wotjak C.T., and Lutz B. Conditional cannabinoid receptor type 1 mutants reveal neuron subpopulation-specific effects on behavioral and neuroendocrine stress responses. Psychoneuroendocrinology 33 (2008) 1165-1170
40. Galve-Roperh I., Aguado T., Palazuelos J., and Guzman M. The endocannabinoid system and neurogenesis in health and disease. Neuroscientist 13 (2007) 109-114
41. Lovinger D.M. Presynaptic modulation by endocannabinoids. Handb Exp Pharmacol (2008) 435-477
42. Gibson H.E., Edwards J.G., Page R.S., Van Hook M.J., and Kauer J.A. TRPV1 channels mediate long-term depression at synapses on hippocampal interneurons. Neuron 57 (2008) 746-759. First report on a retrograde signalling mediated by and endovanilloid and TRPV1.
43. Monory K., Massa F., Egertova M., Eder M., Blaudzun H., Westenbroek R., Kelsch W., Jacob W., Marsch R., Ekker M., et al. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51 (2006) 455-466
44. Katona I., and Freund T.F. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 14 (2008) 923-930
45. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G., Hermann H., Tang J., Hofmann C., Zieglgänsberger W., et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 418 (2002) 530-534
46. Patel S., Roelke C.T., Rademacher D.J., and Hillard C.J. Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. Eur J Neurosci 21 (2005) 1057-1069
47. Hill M.N., Carrier E.J., McLaughlin R.J., Morrish A.C., Meier S.E., Hillard C.J., and Gorzalka B.B. Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J Neurochem 106 (2008) 2322-2336
48. Carter E., and Wang X.J. Cannabinoid-mediated disinhibition and working memory: dynamical interplay of multiple feedback mechanisms in a continuous attractor model of prefrontal cortex. Cereb Cortex 17 Suppl. 1 (2007) i16-i26
49. Deadwyler S.A., and Hampson R.E. Endocannabinoids modulate encoding of sequential memory in the rat hippocampus. Psychopharmacology (Berl) 198 (2008) 577-586
50. Chakrabarti B., Kent L., Suckling J., Bullmore E., and Baron-Cohen S. Variations in the human cannabinoid receptor (CNR1) gene modulate striatal responses to happy faces. Eur J Neurosci 23 (2006) 1944-1948
51. Domschke K., Dannlowski U., Ohrmann P., Lawford B., Bauer J., Kugel H., Heindel W., Young R., Morris P., Arolt V., et al. Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. Eur Neuropsychopharmacol 18 (2008) 751-759
52. Lu A.T., Ogdie M.N., Jarvelin M.R., Moilanen I.K., Loo S.K., McCracken J.T., McGough J.J., Yang M.H., Peltonen L., Nelson S.F., et al. Association of the cannabinoid receptor gene (CNR1) with ADHD and post-traumatic stress disorder. Am J Med Genet B Neuropsychiatr Genet 147B (2008) 1488-1494
53. D'Souza D.C., Perry E., MacDougall L., Ammerman Y., Cooper T., Wu Y.T., Braley G., Gueorguieva R., and Krystal J.H. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29 (2004) 1558-1572
54. Phan K.L., Angstadt M., Golden J., Onyewuenyi I., Popovska A., and de W.H. Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. J Neurosci 28 (2008) 2313-2319
55. Nissen S.E., Nicholls S.J., Wolski K., Rodes-Cabau J., Cannon C.P., Deanfield J.E., Despres J.P., Kastelein J.J., Steinhubl S.R., Kapadia S., et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 299 (2008) 1547-1560
56. Addy C., Rothenberg P., Li S., Majumdar A., Agrawal N., Li H., Zhong L., Yuan J., Maes A., Dunbar S., et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers. J Clin Pharmacol 48 (2008) 734-744
57. Addy C., Wright H., Van L.K., Gantz I., Erondu N., Musser B.J., Lu K., Yuan J., Sanabria-Bohorquez S.M., Stoch A., et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 7 (2008) 68-78
58. Harkany T., Mackie K., and Doherty P. Wiring and firing neuronal networks: endocannabinoids take center stage. Curr Opin Neurobiol 18 (2008) 338-345
59. Berghuis P., Rajnicek A.M., Morozov Y.M., Ross R.A., Mulder J., Urban G.M., Monory K., Marsicano G., Matteoli M., Canty A., et al. Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science 316 (2007) 1212-1216
60. 1 receptors on glutamatergic neurons.
61. Aguado T., Romero E., Monory K., Palazuelos J., Sendtner M., Marsicano G., Lutz B., Guzman M., and Galve-Roperh I. The CB1 cannabinoid receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis. J Biol Chem 282 (2007) 23892-23898
62. Schneider M. Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol 13 (2008) 253-263. Very good overview on the impact of THC during puberty on emotional responses at later age.
63. Huizink A.C., and Mulder E.J. Maternal smoking, drinking or cannabis use during pregnancy and neurobehavioral and cognitive functioning in human offspring. Neurosci Biobehav Rev 30 (2006) 24-41
64. Di Forti M., Morrison P.D., Butt A., and Murray R.M. Cannabis use and psychiatric and cognitive disorders: the chicken or the egg?. Curr Opin Psychiatry 20 (2007) 228-234
65. Long J.Z., Li W., Booker L., Burston J.J., Kinsey S.G., Schlosburg J.E., Pavón F.J., Serrano A.M., Selley D.E., Parsons L.H., et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 5 (2009) 37-44